Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization

American Heart Journal

Volumn 163, Issue 5, 2012, Pages

  Crowley, Matthew J ^a,b   Powers, Benjamin J ^a,b   Myers, Evan R ^a,c   McBroom, Amanda J ^a   Sanders, Gillian D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STUDY DESIGN;

EID: 84861306256     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.02.016     Document Type: Article

References (77)

1. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
2. E. Ambrosioni, C. Borghi, and B. Magnani The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation Study Investigators N Engl J Med 332 1995 80 85
3. L. Kober, C. Torp-Pedersen, and J.E. Carlsen A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 333 1995 1670 1676 (Pubitemid 26001955)
4. M.A. Pfeffer, J.J. McMurray, and E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906 (Pubitemid 37409706)
5. C.I. Coleman, W.L. Baker, and J. Kluger Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease 2009 Agency for Healthcare Research and Quality Rockville (Md)
6. S. Yusuf, K.K. Teo, and J. Pogue Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559 (Pubitemid 351522739)
7. K.A. Robinson, I.J. Saldanha, and N.A. Mckoy Frameworks for determining research gaps during systematic reviews. Methods Future Research Needs Report No. 2. AHRQ Publication No. 11-EHC043-EF 2011 Agency for Healthcare Research and Quality Rockville (Md)
8. Agency for Healthcare Research and Quality Future research needs - methods research series Available at: http://www.effectivehealthcare.ahrq.gov/ index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayProduct& productID=481 Last accessed August 30, 2011
9. R. Gold, E.P. Whitlock, and C.D. Patnode Prioritizing research needs based on a systematic evidence review: a pilot process for engaging stakeholders Health Expect 2011 [Epub ahead of print]
10. B.S. Buckley, A.M. Grant, and C.M. Glazener Case study: a patient-clinician collaboration that identified and prioritized evidence gaps and stimulated research development J Clin Epidemiol 2011 [Epub ahead of print]
11. S. McIntyre, I. Novak, and A. Cusick Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians Dev Med Child Neurol 52 2010 270 275
12. C. Malcolm, K. Knighting, and L. Forbat Prioritization of future research topics for children's hospice care by its key stakeholders: a Delphi study Palliat Med 23 2009 398 405
13. G.D. Sanders, B. Powers, and M. Crowley Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease 2010 Agency for Healthcare Research and Quality Rockville (Md)
14. S. Yusuf, K. Teo, and C. Anderson Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertenisve and Lipid-Lowering Treatment To Prevent Heart Attack Trial JAMA 288 2002 2981 2997
16. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
17. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial Lancet 362 2003 782 788 (Pubitemid 37093919)
18. B.J. Powers, R.R. Coeytaux, and R.J. Dolor Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information J Gen Intern Med 2011 [Epub ahead of print]
19. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
20. B. Pitt, P.A. Poole-Wilson, and R. Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial Lancet 355 2000 1582 1587 (Pubitemid 30240502)
21. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675 (Pubitemid 33126822)
22. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure Lancet 362 2003 759 766 (Pubitemid 37093915)
23. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors Lancet 362 2003 767 771 (Pubitemid 37093916)
24. G. Montalescot, H. Drexler, and R. Gallo Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study Eur Heart J 30 2009 2733 2741
25. C.I. Coleman, W.L. Baker, and J. Kluger Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I 2009 Agency for Healthcare Research and Quality Rockville (Md)
26. Choudhry N. A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies (Post-MI FREEE). ClinicalTrials.gov (ID:NCT00566774).
27. L.J. Haywood, C.E. Ford, and R.S. Crow Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) J Am Coll Cardiol 54 2009 2023 2031
28. J.J. McMurray, R.R. Holman, and S.M. Haffner Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
29. G. Pela, P. Pattoneri, and M. Passera Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study J Cardiovasc Med (Hagerstown) 10 2009 781 786
30. C.V. Rizos, H.J. Milionis, and M.S. Kostapanos Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study Clin Ther 32 2010 492 505
31. M.P. Schneider, T.A. Hua, and M. Bohm Prevention of atrial fibrillation by Renin-angiotensin system inhibition a meta-analysis J Am Coll Cardiol 55 2010 2299 2307
32. P. Verdecchia, P. Sleight, and G. Mancia Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease Circulation 120 2009 1380 1389
33. Davis S. Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes. ClinicalTrials.gov (ID: NCT00574834).
34. Matsubara H. Add-on Effects of Valsartan on Morbi-Mortality (KYOTO HEART Study). ClinicalTrials.gov (ID: NCT00149227).
35. Matsubara H. Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS). ClinicalTrials.gov (ID: NCT00863980).
36. Murohara T. Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance. ClinicalTrials.gov (ID: NCT00129233).
37. Zanchetti A. Prevention of Diabetes and Hypertension (PHIDIAS). ClinicalTrials.gov (ID: NCT00456963).
38. M. Bohm, M. Baumhakel, and K. Teo Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials Circulation 121 2010 1439 1446
39. C. Borghi, A.F. Cicero, and S. Bacchelli Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial Fundam Clin Pharmacol 23 2009 641 648
40. S. Czernichow, T. Ninomiya, and R. Huxley Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial Hypertension 55 2010 1193 1198
41. Kingwell BA. Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease. ClinicalTrials.gov (ID: NCT00681226).
42. H. Arima, C. Anderson, and T. Omae Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial J Hypertens 28 2010 395 400
43. F. Persson, P. Rossing, and H. Reinhard Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria Diabetes Care 32 2009 1873 1879
44. B. Schwander, B. Gradl, and Y. Zollner Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe - the HEALTH model Value Health 12 2009 857 871
45. Fogari R. Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria. ClinicalTrials.gov (ID: NCT01038895).
46. Kashiwagi A. Rationale and Design for Shiga Microalbuminuria Reduction Trial. ClinicalTrials.gov (ID: NCT00202618).
47. Kawamori R. A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes. ClinicalTrials.gov (ID: NCT00144144).
48. M.E. Bertrand, R. Ferrari, and W.J. Remme Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study Am Heart J 159 2010 795 802
49. S. Deftereos, G. Giannopoulos, and C. Kossyvakis Effect of quinapril on in-stent restenosis and relation to plasma apoptosis signaling molecules Am J Cardiol 105 2010 54 58
50. A. Hirohata, K. Yamamoto, and T. Miyoshi Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial J Am Coll Cardiol 55 2010 976 982
51. Egstrup K. Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study). ClinicalTrials.gov (ID: NCT00125645).
52. Ogawa H. A Trial of Telmisartan Prevention of Cardiovascular Disease (ATTEMPT-CVD). ClinicalTrials.gov (ID: NCT01075698).
53. Sakamoto T. Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial. ClinicalTrials.gov (ID: NCT00139386).
54. C. Boersma, A.A. Voors, and S.T. Visser Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data Am J Cardiovasc Drugs 10 2010 49 54
55. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151:1-10, W1-2.
56. S. De Cosmo, N. Motterlini, and S. Prudente Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT Diabetes 58 2009 2920 2929
57. U.F. Mehdi, B. Adams-Huet, and P. Raskin Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 2009 2641 2650
58. Antonopoulos P. Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients. ClinicalTrials.gov (ID: NCT00961207).
59. Camargo E. Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients. ClinicalTrials.gov (ID: NCT00427271).
60. Chen N. Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 (FLIP). ClinicalTrials.gov (ID: NCT00565396).
61. Fried L. VA NEPHRON-D: Diabetes iN Nephropathy Study. ClinicalTrials.gov (ID:NCT00555217).
62. Hou F. Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency (SDBRAS). ClinicalTrials.gov (ID: NCT00630708).
63. Remuzzi G. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). ClinicalTrials.gov (ID: NCT00494715).
64. Ruggenenti P. Preventing Microalbuminuria in Type 2 Diabetes (VARIETY). ClinicalTrials.gov (ID: NCT00503152).
65. Zatz R. Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus. ClinicalTrials.gov (ID: NCT00419835).
66. Gupta M. Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - the ROSITEL Study. ClinicalTrials.gov (ID: NCT00486187).
67. K.M. Donner, T.P. Hiltunen, and T. Suonsyrja CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men J Hypertens 27 2009 2001 2009
68. B.G. Nordestgaard, K. Kontula, and M. Benn Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study Pharmacogenet Genomics 20 2010 77 85
69. Bhansali A. Association of Angiotensin II Type 1 R Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes. ClinicalTrials.gov (ID: NCT01069549).
70. D.A. de Luis, R. Conde, and M. Gonzalez-Sagrado Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients Nutr Hosp 25 2010 275 279
71. R. Fogari, A. Zoppi, and I. Ferrari Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients Horm Metab Res 41 2009 893 898
72. T. Hamada, E. Mizuta, and T. Kondo Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients Arzneimittelforschung 60 2010 71 75
73. C.V. Rizos, H.J. Milionis, and M.S. Kostapanos Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study Clin Ther 32 2010 492 505
74. Lim D. Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes. ClinicalTrials.gov (ID: NCT00599885).
75. S.G. Chrysant Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study Clin Drug Investig 30 2010 473 482
76. Golik A. ACEIs and ARBs Treatment in Diabetic Patients - Drug Interactions and Adverse Drug Effects. ClinicalTrials.gov (ID: NCT00437775).
77. N.J. Brown, S. Byiers, and D. Carr Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema Hypertension 54 2009 516 523